Incyte

Global LAG-3 inhibitors market to exceed USD 3 billion by 2029, driven by the approval of Opdualag, the first LAG-3 therapy, and ongoing clinical trials evaluating LAG-3 inhibitors in combination therapies. Key players include Bristol Myers Squibb, Symphogen A/S, and Hoffmann-La Roche.

Aquestive Therapeutics hosted a virtual investor day, highlighting its Anaphylm and AQST-108 candidates. The company completed enrollment for Anaphylm's OAS challenge study and plans to submit an NDA in Q1 2025. AQST-108, targeting Alopecia areata, completed its first human study, with a pre-IND meeting scheduled for Q1 2025. H.C. Wainwright raised Aquestive's price target to $10 with a Buy rating, attributing a 30% approval probability to AQST-108 and 85% to Anaphylm. The FDA approved treatments for severe alopecia areata in 2022 and 2023, positioning AQST-108 to capture market share if approved.

Regeneron Pharmaceuticals' P/E, P/B, and P/S ratios are lower than industry averages, suggesting potential undervaluation. High ROE, EBITDA, and gross profit indicate strong profitability, but low revenue growth raises concerns about future performance.

Oncolytics Biotech Inc. advances pelareorep therapy, showing significant survival benefits in breast cancer patients. Other biotech companies like Nurix, Incyte, Regeneron, and Foghorn also report promising developments in cancer treatments.

Graft versus Host Disease Market to grow at 9.9% CAGR (2020-2034), driven by branded therapies, strong pipeline, and increased awareness. Market size in the US was $1 billion in 2023, expected to grow at 7.4% CAGR (2024-2034). Emerging therapies like Axatilimab and CSL964 to transform market. Key companies include Equillium, Biocon, Takeda, and CSL Behring.

The graft versus host disease market is growing due to the adoption of branded therapies like JAKAFI, IMBRUVICA, ORENCIA, and REZUROCK, a strong pipeline with over 10 new drugs expected to launch, and increased awareness of GvHD management. Innovative treatments and ongoing research aim to address unmet needs in this complex condition.

Mantle cell lymphoma (MCL) treatment outcomes improve with novel targeted therapies like BTK inhibitors. DelveInsight's 'Mantle Cell Lymphoma Pipeline Insight 2024' covers 20+ companies developing 22+ therapies, including Venetoclax and ADI-001. Key events include AstraZeneca's Phase III ECHO trial and BeiGene's AACR presentation.